At the 2026 National ICE-T Conference in Orlando, pharmacists and clinicians addressed a central operational hurdle in cellular therapy: deciding when to escalate treatment for CAR T-cell-related toxicities without definitive prophylactic thresholds. According to Tiba Al Sagheer, PharmD, BCOP, BCACP, pharmacy quality improvement coordinator for transplant and cellular therapy at Miami Cancer Institute of Baptist Health South Florida, emerging biomarkers are shaping modern precision approaches, though clinicians still lack a clear trigger point for preventing delayed neurotoxicity.
Biomarkers and Precision Approaches in CAR T Toxicity
Deciding when to intervene in CAR T-cell therapy toxicities relies heavily on emerging biomarker data, according to Al Sagheer. Speaking with CancerNetwork, she noted that the 2026 American Society for Transplantation and Cellular Therapy (ASTCT) consensus guidance document attempts to organize these markers into practical categories. The framework stratifies testing needs into mandatory “must have” or “should have” items, alongside secondary options categorized as “can have” or “nice to have.” This structure helps separate routine clinical monitoring markers from tests reserved strictly for research purposes.
Did you know? The 2026 ASTCT consensus guidance categorizes biomarker testing into distinct tiers to help clinical teams prioritize routine patient care diagnostics over experimental research assays.
The Challenge of Setting Prophylactic Thresholds
Despite advances in biomarker classification, clinicians still face a significant knowledge gap regarding prophylaxis. Al Sagheer emphasized that the field currently lacks a definitive answer or threshold—whether measured by absolute lymphocyte count (ALC) or alternative indicators—to tell care teams when to pull the trigger on preventive agents for delayed neurotoxicity. Because effective treatments for these delayed neurological complications remain limited, defining an accurate timing threshold is an active area of investigation.
Differentiating CRS from IEC-HS
Another major operational hurdle in cellular therapy management involves distinguishing immune effector cell (IEC)–associated hemophagocytic lymphohistiocytosis (HLH)–like syndrome (IEC-HS) from standard cytokine release syndrome (CRS). Al Sagheer pointed out that clinical differentiation often hinges on specific laboratory cutoffs. Specifically, a ferritin level slightly above 7,000—precisely 7,420, according to her conference presentation—serves as the clinical tipping point where clinicians should switch diagnoses, initiate targeted treatment for IEC-HS, and escalate overall patient care.
Pro Tip: Monitor ferritin trajectories closely during cellular therapy recovery. A threshold approaching 7,420 may signal the need to pivot from standard CRS management to specific IEC-HS escalation protocols.
Frequently Asked Questions
What is the primary challenge in CAR T toxicity management?
According to Tiba Al Sagheer, the primary challenge is the lack of a definitive threshold or trigger point for initiating prophylaxis against delayed neurotoxicities, as well as accurately differentiating between CRS and IEC-HS.
How does the ASTCT consensus guidance help clinicians?
The 2026 ASTCT consensus guidance document stratifies emerging biomarkers into clear operational tiers—ranging from essential routine tests to research-only assays—helping clinical teams manage diagnostic workflows.
What ferritin level indicates IEC-HS escalation?
A ferritin cutoff slightly above 7,000 (specifically 7,420) is the threshold identified for switching treatment strategies to address IEC-HS.
Want to stay updated on the latest breakthroughs in oncology pharmacy and cellular therapy management? Subscribe to our newsletter or explore our clinical updates archive for more expert coverage from major medical conferences.
Related reading